Market Place
Sourcing Support
Everest’s EVER001 Shows Promise in Primary Membranous Nephropathy
03 Dec 2024 //
PR NEWSWIRE
Everest Medicines to Hold Calls on EVER001 Data for Nephropathy
27 Nov 2024 //
PR NEWSWIRE
Everest Medicines Announces Interim Results for First Half of 2024
27 Aug 2024 //
PR NEWSWIRE
Everest Medicines Initiates IIT For mRNA Cancer Vaccine EVM16
22 Aug 2024 //
BIOSPACE
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
05 Aug 2024 //
PR NEWSWIRE
Calliditas Partner Everest Launches Nefecon In China
14 May 2024 //
PR NEWSWIRE
Everest Medicines Announces Financial Results for Full Year 2023
27 Mar 2024 //
PR NEWSWIRE
Singapore gives nod to China-based Everest Medicines` drug for nephropathy
20 Mar 2024 //
BIOSPECTRUM ASIA
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN
19 Mar 2024 //
PR NEWSWIRE
Everest Medicines Strengthens Management Team
17 Mar 2024 //
PR NEWSWIRE
Calliditas Announces FDA Grants an Seven-Year Orphan Drug Period for Nefecon
11 Mar 2024 //
PR NEWSWIRE
Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
10 Mar 2024 //
PR NEWSWIRE
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28
05 Mar 2024 //
PR NEWSWIRE
Everest Medicines and Kezar Receive IND Approval from NMPA for PALIZADE Trial
26 Feb 2024 //
BUSINESSWIRE
Everest Medicines Announces Termination of Agreements with Providence
18 Feb 2024 //
PR NEWSWIRE
Everest Medicines Announces Revenue Expected to be Between RMB124M & RMB126M
21 Jan 2024 //
PR NEWSWIRE
Everest Medicines Announces New Drug Application Acceptance of Nefecon
26 Dec 2023 //
PR NEWSWIRE
Calliditas Announces Nefecon to Significantly Slow Kidney Function Decline
20 Dec 2023 //
PR NEWSWIRE
Everest Medicines Announces Investigational NDA Acceptance of Zetomipzomib
03 Dec 2023 //
PR NEWSWIRE
Everest Medicines Announces China NMPA`s Approval of Nefecon
23 Nov 2023 //
PR NEWSWIRE
Everest Medicines Announces New Drug Application Approval for Nefecon
27 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon
26 Oct 2023 //
PR NEWSWIRE
Everest Medicines` Licensing Partner Pfizer Announces FDA Approves Etrasimod
15 Oct 2023 //
PR NEWSWIRE
Everest Medicines` Partner Calliditas Presents Data from NefIgArd Phase 3 Trial
04 Oct 2023 //
PR NEWSWIRE
Everest Medicines Announces Approval of XERAVA® in Taiwan
27 Sep 2023 //
PR NEWSWIRE
Kezar and Everest Medicines Enter into an Agreement to Develop Zetomipzomib
20 Sep 2023 //
BUSINESSWIRE
Everest Announces NMPA Recommends Priority Review for Cefepime-Taniborbactam
19 Sep 2023 //
PR NEWSWIRE
Everest Medicines Announces NDA Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon
24 Aug 2023 //
PR NEWSWIRE
Everest Medicines Announces Interim Results for First Half of 2023
23 Aug 2023 //
PR NEWSWIRE
Everest Medicines Announces Calliditas Receives FDA Priority Review for Nefecon
20 Aug 2023 //
PR NEWSWIRE
Calliditas Announces Full Results From NefIgArd Phase 3 Trial published
17 Aug 2023 //
PR NEWSWIRE
Venatorx Receives FDA Acceptance of NDA for Cefepime-Taniborbactam
15 Aug 2023 //
PR NEWSWIRE
Everest Medicines to Announce First Half 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Everest Medicines Announces Completion of Patient Enrollment in Nefecon® China Open Label Extension Study
31 Jul 2023 //
PR NEWSWIRE
Everest Medicines Announces Commercial Launch and First Prescription for XERAVA
26 Jul 2023 //
PR NEWSWIRE
Everest Medicines` Partner Calliditas Makes Data Presentations on Nefecon
20 Jun 2023 //
PR NEWSWIRE
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer
15 Jun 2023 //
PR NEWSWIRE
Everest Medicines Announces Completion in Ph 3 Trial of Etrasimod in Asia
16 May 2023 //
PR NEWSWIRE
China marks beginning of new treatment for primary immunoglobulin A nephropathy
24 Apr 2023 //
BIOSPECTRUM ASIA
Everest Medicines Launches Nefecon in China`s Hainan Boao Pilot Zone
23 Apr 2023 //
PR NEWSWIRE
Everest Medicines Announces Partnership with Shanghai Pharma Subsidiary
18 Apr 2023 //
PR NEWSWIRE
Everest Medicines Announces NDA Acceptance for Nefecon
05 Apr 2023 //
PR NEWSWIRE
Everest Announces Financial Results for Full Year Ended December 31, 2022
30 Mar 2023 //
PR NEWSWIRE
Everest Receives Upfront Payment from Gilead for Trodelvy-Related Transaction
26 Mar 2023 //
PR NEWSWIRE
Everest Medicines partners with Guangdong Academy of Medical Sciences
24 Mar 2023 //
BIOSPECTRUM ASIA
Everest Medicines Announces Approval of Xerava in China
17 Mar 2023 //
PR NEWSWIRE
Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
15 Mar 2023 //
PR NEWSWIRE
Calliditas Reports Positive Topline Results from Phase 3 NefIgArd Trial
13 Mar 2023 //
PR NEWSWIRE
Everest Announces Silicon Valley Bank Developments Have Minimal Impact on Company
12 Mar 2023 //
PR NEWSWIRE
Everest debuts $130M mRNA vaccine plant in China
02 Mar 2023 //
FIERCE PHARMA
Everest Announces South Korea Grants Fast Track Review Designation to Nefecon
09 Feb 2023 //
PR NEWSWIRE
Everest Medicines Announces Top-line Data from Phase I Study of EVER206
17 Jan 2023 //
PR NEWSWIRE
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation
03 Jan 2023 //
PR NEWSWIRE
Everest Medicines to Hold New Corporate Strategy Online Conference Calls
29 Dec 2022 //
PR NEWSWIRE
Everest Medicines begins production at its new $129M+ mRNA vaccine
29 Dec 2022 //
ENDPTS
Everest Medicines Commences Operations at its mRNA Vaccine MFG Facility
27 Dec 2022 //
PRNEWSWIRE
Everest Medicines` Licensing Partner Pfizer Announces FDA and EMA
21 Dec 2022 //
PRNEWSWIRE
Everest Medicines Announces New mRNA Rabies Vaccine Program
14 Dec 2022 //
PRNEWSWIRE
Everest Medicines Announces Major Regulatory Updates in Taiwan for Nefecon
27 Nov 2022 //
PRNEWSWIRE
Everest Medicines Announces NDA Acceptance by China NMPA for Nefecon
14 Nov 2022 //
PRNEWSWIRE
